Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SGHT vs WOK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGHT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–1 Matrix Metrics)

SGHT Overall Winner 6-Pillar Tally: SGHT 4 – 2 WOK Matrix Metrics: SGHT 7 – 1 WOK

As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.59 (N/M Forward P/E, -20.2% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin).

  • Defensive Composite Rating Caution: Although SGHT compares more favorably head-to-head, both SGHT (35.1/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGHT vs WOK
SGHT NASDAQ Head-to-Head Winner
Sight Sciences, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$10.59
-2.22% 1D
Market Cap $601.9M
TTM Revenue $88M
Forward P/E N/M
Beta / 30D Vol 1.05β · 45% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 32.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.0% over 20 days), RSI 64
RSI-14: 64.1 · SMA20: $9.74 · SMA50: $9.01
WOK NASDAQ
WORK Medical Technology Group LTD Class A Ordinary Shares
Surgical & Medical Instruments & Apparatus
$1.23
+2.5% 1D
Market Cap $5.4M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 38.49β · 153% Vol
Unified Composite Score
25.6 / 100 SELL
Tech 5.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.1 · SMA20: $1.13 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (SGHT 4 – 2 WOK)

Columns: Metric · SGHT · WOK
1. Valuation Multiples WOK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.4x 0.5x
2. Growth & Scale SGHT
Revenue Growth (YoY) +25.2% +19.1%
Earnings Growth (YoY) +0.0% -95.0%
TTM Revenue (USD) $88M $11M
Market Cap $601.9M $5.4M
3. Profitability & Quality SGHT
Gross Margin 87.7% 17.0%
Operating Margin -20.2% -41.7%
Net Profit Margin -32.1% -41.9%
Return on Equity (ROE) -50.1% -19.2%
4. Balance Sheet & Cash Flow SGHT
Cash Generation (TTM) -$17M -$3.4M EBITDA
Cash Flow Margin -19.1% -31.4% EBITDA Mgn
Net Cash / Leverage $35M Net Cash $1855.16 Book/Sh · -19.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGHT
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 78.7% (8th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat WOK
OpEx & R&D Intensity N/A 58.7% of Rev ($6.3M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGHT (7) vs WOK (1)
Institutional Metric SGHT WOK Criterion Row Edge
Market Capitalization
Scale
$601.9M $5.4M Larger Scale SGHT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+25.2% +19.1% Higher Growth SGHT
Operating Margin (TTM)
Profitability
-20.2% -41.7% Higher Margin SGHT
Net Profit Margin
Profitability
-32.1% -41.9% Higher Margin SGHT
Return on Equity (ROE)
Capital Efficiency
-50.1% -19.2% Higher ROE WOK
52-Week Range Position
Momentum
88% ($3–$12) 16% ($0–$7) Stronger Trend SGHT
Beta / 30D Volatility
Risk Regime
1.05β · 45% Vol 38.49β · 153% Vol Lower Realized Risk SGHT
Unified Institutional Score
Composite Signal
35.1 / 100 (SELL) 25.6 / 100 (SELL) Higher Composite SGHT
Trailing 12M Revenue (USD)
Operating Scale
$88M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% 17.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.4x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($35M Net Cash) -$3.4M EBITDA ($1855.16 Book/Sh · -19.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGHT +15.06 pp
SGHT: +27.9% · WOK: +12.84%
3M Horizon SGHT +72.92 pp
SGHT: +28.83% · WOK: -44.09%
6M Horizon WOK +105.78 pp
SGHT: +117.9% · WOK: +223.68%
1Y Horizon SGHT +122.26 pp
SGHT: +50.21% · WOK: -72.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGHT vs WOK. Trailing 12-month operating profitability (SGHT -20.2% vs WOK -41.7%) and valuation multiples (SGHT N/M vs WOK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SGHT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$88M
Gross Margin87.7%
Op. Margin-20.2%
ROE / Fwd P/E-50.1% · N/M
WOK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross Margin17.0%
Op. Margin-41.7%
ROE / Fwd P/E-19.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGHT BREAKOUT
33d in phase · OBV ACCUMULATION
Current IV 78.7%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WOK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGHT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $601.9M market capitalization and -20.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
WOK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.4M market capitalization and -41.7% operating margin.
OpEx & R&D Reinvestment 58.7% of Rev ($6.3M)
90D Engineering Disclosures 0 Published

Investor FAQ SGHT vs WOK Key Questions & Quantitative Answers

As of Nov 16, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over WORK Medical Technology Group LTD Class A (WOK) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SGHT carries a Unified Composite Score of 35.1/100 (SELL) at $10.59 (N/M Forward P/E, -20.2% operating margin), whereas WOK carries 25.6/100 (SELL) at $1.23 (N/M Forward P/E, -41.7% operating margin). Defensive Composite Rating Caution: Although SGHT compares more favorably head-to-head, both SGHT (35.1/100 SELL) and WOK (25.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SGHT leads the Growth & Scale pillar: SGHT posts +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin), compared with WOK at +19.1% YoY revenue growth and -95.0% YoY earnings growth on $11M TTM revenue (17.0% gross margin, -41.7% operating margin). On trailing 12-month operating scale, SGHT generates $88M in USD-normalized revenue versus $11M for WOK. In operating R&D and SG&A reinvestment, SGHT deploys N/A (0 90-day corporate R&D disclosures) versus 58.7% of Rev ($6.3M) (0 disclosures) for WOK.

WOK screens cheaper on headline valuation multiples. SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-19.1% FCF margin), whereas WOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-31.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGHT (-50.1% ROE) versus WOK (-19.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 45% Vol realized risk). By comparison, WOK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (38.49β · 153% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

WORK Medical Technology Group LTD Class A Ordinary Shares (WOK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.